Skip to main content
SpringerLink
Log in

Polyphenon® E

Eine neue topische Therapie für Condylomata acuminata

Polyphenon® E

A new topical therapy for condylomata acuminata

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Therapie von genitalen Warzen (Condylomata acuminata) ist trotz der Einführung der topischen Therapie mit Imiquimod-5%-Creme nicht völlig zufriedenstellend, insbesondere wegen unerwünschter lokaler und systemischer Nebenwirkungen etablierter Behandlungsformen. Mit der Entwicklung der Polyphenon® E-15%-Salbe ist eine Weiterentwicklung zur optimierten und patientenfreundlicheren Behandlung genitaler Warzen gelungen. Polyphenon® E ist ein Gemisch aus verschiedenen Polyphenolen/Catechinen des grünen Tees (Camilla sinensis), denen antioxidative, antientzündliche sowie antiproliferative und krebshemmende Aktivitäten zuerkannt werden. Sicherheit und Wirksamkeit von Polyphenon® E wurden in 3 placebokontrollierten klinischen Studien an insgesamt 1400 Patienten mit genitalen Warzen aus Europa, Nord- und Südamerika sowie Südafrika untersucht. Die Wirksamkeit bezüglich der völligen Abheilung aller genitalen Warzen betrug 54,9%. Im Vergleich hierzu heilten placebobehandelte Genitalwarzenpatienten zu 35,4% (p<0,001; kombinierte Studiendaten) ab. Die Rezidivrate betrug 6,2%. Besondere Vorteile bietet Polyphenon® E aufgrund seiner Nebenwirkungsarmut. Systemische Nebenwirkungen sind unwahrscheinlich. Lokale Reaktionen sind mild bis mäßig und nur kurzzeitig nachweisbar. „Therapieferien“ und Abwaschen der Polyphenon® E-behandelten Hautareale sind nicht notwendig. Außerdem bestehen keine Probleme bei der Therapie nicht zirkumzidierter Männer.

Abstract

Treatment of genital warts (condylomata acuminata) is still not completely satisfactory, despite the introduction of imiquimod 5% cream. With the development of Polyphenon® E 15% ointment, progress has been made towards optimized, patient-friendly treatment of genital warts. Polyphenon® E is a mixture of different polyphenols/catechins from green tea extracts (Camilla sinensis), which are known to have antioxidative, antiinflammatory, anti-proliferative and anticancer activities. In 3 placebo-controlled clinical studies safety and efficacy of Polyphenol® E 15% ointment was studied in a total of 1400 patients with genital warts from Europe, North- and South America as well as South Africa. Complete responses with total healing of genital warts were seen in 54.9% of the patients in contrast to 35.4% of patients receiving placebo (p >0.001) (Combined study data). The recurrence rate was 6.2%. Polyphenon® E offers special advantages with regard to its very good safety profile. Systemic adverse reactions are unlikely. Mild to moderate local reactions are of short duration. “Drug-holidays” are not necessary and the ointment does not have to be washed off. There is no contraindication for uncircumcised men with genital warts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Gross G, Barrasso R (1997) Human papillomavirus infection. A clinical atlas. Ulstein-Mosby, Wiesbaden Berlin Heidelberg

  2. Clarke P, Ebel C, Catotti DN, Stewart S (1996) The psychosocial impact of human papillomavirus infection: implications for health care providers. Int. J STD AIDS 7: 197–200

    Article  CAS  Google Scholar 

  3. Kjaer SK, Dahl, C, Engholm G et al. (1992) Case-control study of risk factors for cervical neoplasia in Denmark. II. Role of sexual activity, reproductive factors and venereal infections. Cancer Causes Control 3: 339–348

    Article  PubMed  CAS  Google Scholar 

  4. Gross G, Ikenberg H, Gissmann L, Hagedorn M (1985) Papillomavirus infection of the anogenital region: correlation between histology, clinical picture and virus type. Proposal of a new momenclature. J Invest Dermatol 85(2): 147–152

    Article  PubMed  CAS  Google Scholar 

  5. Gross G (2007) Condylomata acuminata und andere HPV-assoziierte Krankheitsbilder von Genitale, Anus und Harnröhre. Leitlinien der Deutschen STD-Gesellschaft in Zusammenarbeit mit der Deutschen Dermatologischen Gesellschaft und der Paul-Ehrlich-Gesellschaft. Hautarzt 58: 179–186

    Article  PubMed  CAS  Google Scholar 

  6. Edwards L, Ferenczy A, Eron L et al. (1998) Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 134: 25–30

    Article  PubMed  CAS  Google Scholar 

  7. Krüger–Kjaer S, Nam Tran T, Tryggradottir T et al. (2007) The burden of genital warts: a study of nearly 70 000 women from the general female population in the 4 Nordic countries. J Infect Dis 196: 1447–1454

    Article  Google Scholar 

  8. Chuang TY, Perry HO, Kurland LT, Ilstrup DM (1984) Condylomata acuminatum in Rochester, Minn., 1950–1978. I Epidermiology and clinical features. Arch Dermatol 120: 469–475

    Article  PubMed  CAS  Google Scholar 

  9. Simms I, Fairley CK (1997) Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med 73(5): 365–367

    PubMed  CAS  Google Scholar 

  10. Koshiol JE, Laurent SA, Pimenta JM (2004) Rate and predictors of new genital warts claims and genital warts – related health care utilization among privately insured patients in the United States. Sex Transm Dis 31: 748–752

    Article  PubMed  Google Scholar 

  11. Insinga RP, Dasbach EJ, Myers ER (2003) The health and economic burden of genital warts in a set of private health planes in the United States. Clin Infect Dis 36: 1397–1403

    Article  PubMed  Google Scholar 

  12. Von Krogh G, Lacey CJ, Gross G et al. (2000) European course on HPV associated pathology: Guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 76: 162–168

    Article  Google Scholar 

  13. Gross G (2007) Bedeutung der prophylaktischen HPV-Vakzine für die Dermatologie und Venerologie. Hautarzt 58(6): 507–514

    Article  PubMed  CAS  Google Scholar 

  14. Lacey CJN (2005) Therapy for genital human papillomavirus-related disease. J Clin Virol 32 S: S82–S90

    Article  CAS  Google Scholar 

  15. Pathirana et al. (in Vorbereitung) AWMF S3-Leitlinie: „Impfprävention HPV-assoziierter Neoplasien“. HPV-Management-Forum, AG der Sektion Antivirale Chemotherapie der Paul-Ehrlich-Gesellschaft

  16. Hildesheim A, Herrero R, Wacholder S et al. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298(7): 743–753

    Article  PubMed  CAS  Google Scholar 

  17. Graham HN (1992) Green tea composition, consumption and polyphenol chemistry. Prev Med 21: 334–350

    Article  PubMed  CAS  Google Scholar 

  18. Chen CW, Ho CT (1994) Antioxidant properties of poyphenols extracted from green and black teas. J Food Lipids 2: 35–46

    Article  Google Scholar 

  19. Lin JK, Liang YC (2000) Cancer chemoprevention by tea polyphenols. Proc Natl Counc ROC (B) 24(1): 1–13

    Google Scholar 

  20. Nakane H, Ono K (1989) Differential inhibition of HIV-reverse transcriptase and various DNA and RNA polymerases by some catechin derivatives. Nucleic Acids Symp Ser 21: 115–116

    PubMed  CAS  Google Scholar 

  21. Ahn WS, Huh SW, Bae SM et al. (2003) A major constituent of green tea, EGCG inhibits the growth of a human cervical cancer cell line CaSki cells, through apoptosis, G1 arrest and regulation of gene expression. DNA Cell Biology 22(3): 217–222

    Article  CAS  Google Scholar 

  22. Sah JF, Balasubramanian S, Eckert RL, Rorke EA (2004) Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 26;279(13): 12755-12762

    Google Scholar 

  23. Gross G, Meyer KG, Pres H et al. (2007) A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon® E in the treatment of external gential warts. J EADV 21: 1404–1412

    CAS  Google Scholar 

  24. Moore RA, Edwards JE, Hopwood J, Hicks D (2001) Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis 1: 3

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Venerologie der Universität Rostock, Augustenstraße 80–85, 18055, Rostock, Deutschland

    G. Gross

Authors
  1. G. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Gross.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gross, G. Polyphenon® E. Hautarzt 59, 31–35 (2008). https://doi.org/10.1007/s00105-007-1456-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-007-1456-0

Schlüsselwörter

Keywords

Search

Navigation